A triple-drug fixed-dose salvage regimen is almost always effective at curing hepatitis C infection in patients who have failed therapy with nonstructural protein 5A (NS5A) inhibitors, researchers have found.
Sustained viral remission rates at 12 weeks (SVR12) were nearly 100% with the regimen (sofosbuvir-velpatasvir-voxilaprevir [Vosevi, Gilead]) and not substantially affected by the presence of cirrhosis, resistance-associated substitutions (RAS) or any of the prior regimens to which patients